- Nabriva Therapeutics (NASDAQ:NBRV) initiated with Buy rating and $20 (150% upside) price target by SunTrust citing potential $700M in peak sales for CABP candidate lefamulin.
- Walgreens Boots Alliance (NASDAQ:WBA) initiated with Buy rating and $95 (18% upside) price target by Loop Capital.
- WellCare Health Plans (NYSE:WCG) initiated with Overweight rating and $195 (15% upside) price target by Cantor Fitzgerald.
- Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Neutral rating and $144 (3% downside risk) price target by H.C. Wainwright.
- CVS Health (NYSE:CVS) initiated with Hold rating by Loop Capital.
- Patterson Companies (NASDAQ:PDCO) upgraded to Neutral with a $40 (0% upside) price target by UBS.
- Stryker (NYSE:SYK) upgraded to Hold by Needham.
- Adamas Pharmaceuticals (NASDAQ:ADMS) price target raised to $55 (287% upside) by Cowen after GOCOVRI approval in the U.S. Price target raised to $33 (132% upside) from $29 by JMP Securities.
- Aratana Therapeutics (NASDAQ:PETX) price target lowered to $10 (86% upside) from $15 by Lake Street citing the transfer of Galliprant manufacturing to Elanco by year-end.
- Source: Bloomberg
- Now read: A Double-Digit Dividend Grower On My Watch List
Original article